Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 1.00 |
| ▸ | ABL1 | P00519 | 12/20 | 1.00 |
| ▸ | KIT | P10721 | 9/20 | 1.00 |
| ▸ | BCR | P11274 | 9/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.82 |
| ▸ | EGFR | P00533 | 2/20 | 0.80 |
| ▸ | PRKCA | P17252 | 1/20 | 0.80 |
| ▸ | KDR | P35968 | 2/20 | 0.77 |
| ▸ | PLK4 | O00444 | 1/20 | 0.77 |
| ▸ | DDX3X | O00571 | 1/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.77 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.77 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.77 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | CA1 | P00915 | 1/20 | 0.77 |
| ▸ | CA2 | P00918 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | ALB | P02768 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4396677 | 0.99 | PDGFRA (0.98) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL3065290 | 0.94 | PDGFRA (0.89) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL3860423 | 0.94 | PDGFRA (0.88) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL3860520 | 0.93 | PDGFRA (0.87) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL27804782 | 0.92 | PDGFRA (0.85) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL805395 | 0.92 | PDGFRA (0.85) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL5189023 | 0.92 | PDGFRA (0.85) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL25281830 | 0.91 | PDGFRA (1.00) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL14292529 | 0.91 | PDGFRA (0.84) | PDGFRAABL1KITBCRPDGFRB | |
| SCHEMBL21248036 | 0.91 | PDGFRA (0.84) | PDGFRAABL1KITBCRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-111039921-A | Synthesis process of imatinib and imatinib mesylate | 杭州沧海帆医药科技有限公司 | 2020-04-21 | — | — | CN | claimed |
| CN-110559299-A | composition containing pyridyl pyrimidinamine compound and application thereof | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| CN-110559443-A | composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| WO-2011095835-A1 | HIGHLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-08-11 | — | — | WO | claimed |
| US-7674901-B2 | Process for preparation of imatinib base | INSTYTUT FARMACEUTYCZNY (PL) | 2010-03-09 | — | — | US | claimed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| CN-1706840-A | Methylsulfonate of pyrimidine derivative and its prepn process, application and medicine composition | HONGZHOU XINRUIJIA BIOMEDICINE (CN) | 2005-12-14 | — | — | CN | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| CN-113518771-A | Method for introducing deuterated lower alkyl into amine part of compound containing secondary amine | 大塚制药株式会社 | 2021-10-19 | — | — | CN | disclosed |
| WO-2020184670-A1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | 大塚製薬株式会社 | 2020-09-17 | — | — | WO | disclosed |
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| WO-2004013633-A2 | METHOD FOR ISOLATING ATP BINDING PROTEINS BY MEANS OF IMMOBOLIZED PROTEIN INHIBITORS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | disclosed |
| EP-1322634-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002022597-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | PDGFRA 2586/4885ABL1 901/4885KIT 4548/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | PDGFRA 2913/4885ABL1 904/4885KIT 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.